SCHEMBL9967759

SCHEMBL9967759

CC(C)CCCc1ccccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.61
SLC6A4 P31645 2/20 0.61
SLC6A3 Q01959 2/20 0.61
AOC3 Q16853 1/20 0.52
TAAR1 Q96RJ0 3/20 0.50
CASR P41180 2/20 0.43
IDO1 P14902 3/20 0.43
PNMT P11086 1/20 0.43
KCNH2 Q12809 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
HRH2 P25021 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HRH1 P35367 1/20 0.43
OPRM1 P35372 1/20 0.43
DRD3 P35462 1/20 0.43
OPRK1 P41145 1/20 0.43
HTR2B P41595 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6680457 0.88 SLC6A2 (0.71) SLC6A2SLC6A4SLC6A3AOC3TAAR1
SCHEMBL7637846 0.85 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3AOC3LMNA
Bromide SCHEMBL14833289 0.83 SLC6A2 (0.77) SLC6A2SLC6A4SLC6A3AOC3TAAR1
SCHEMBL11871543 0.80 SLC6A2 (0.39) SLC6A2SLC6A4SLC6A3AOC3LMNA
SCHEMBL7637528 0.79 HIF1A (0.41) SLC6A2SLC6A4SLC6A3LMNA
SCHEMBL1822278 0.78 TAAR1 (0.62) SLC6A2SLC6A4SLC6A3AOC3TAAR1
SCHEMBL6527163 0.77 DPP4 (0.47) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL7632660 0.77 HIF1A (0.43) SLC6A2SLC6A4SLC6A3LMNA
SCHEMBL256701 0.77 TAAR1 (0.56) SLC6A2SLC6A4SLC6A3AOC3TAAR1
SCHEMBL30899680 0.77 HIF1A (0.43) SLC6A2SLC6A4SLC6A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 US disclosed
US-20150173359-A1 SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES BAYER IP GMBH (DE) 2015-06-25 US disclosed
US-20150173359-A1 SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES BAYER IP GMBH (DE) 2015-06-25 US disclosed
US-9006265-B2 Substituted fused pyrimidinones and dihydropyrimidinones BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-14 US disclosed
US-9006265-B2 Substituted fused pyrimidinones and dihydropyrimidinones BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-14 US disclosed
US-20120157306-A1 Substituted Fused Pyrimidinones and Dihydropyrimidinones BAYER CROPSCIENCE AG (DE) 2012-06-21 US disclosed
US-20120157306-A1 Substituted Fused Pyrimidinones and Dihydropyrimidinones BAYER CROPSCIENCE AG (DE) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150173359-A1 SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES DHPS, FDPS, DPYD SLC6A2 3131/4885SLC6A4 2616/4885SLC6A3 2265/4885
US-20120157306-A1 Substituted Fused Pyrimidinones and Dihydropyrimidinones DHPS, FDPS, DPYD SLC6A2 3131/4885SLC6A4 2616/4885SLC6A3 2265/4885
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G SLC6A2 4169/4885SLC6A4 4539/4885SLC6A3 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.